Indian drugmaker Anthem Biosciences' ANTH.NS $395 million IPO was fully subscribed on the second day of bidding on Tuesday, ...

Anthem Biosciences Ltd, a CRDMO founded in 2006, offers end-to-end drug discovery-to-manufacturing services and specialises in fermentation-based active pharmaceutical ingredients (APIs) for global ...

Anthem Biosciences is raising ₹3,395 crore through an initial share sale, which comprises of entirely an offer-for-sale by ...

The initial public offering of Anthem Biosciences Ltd. has been subscribed to nearly eight times the offer on its third and ...

Check latest subscription status, grey market premium (GMP), allotment date, listing date, and other key details here ...

Today is the last day for investors to subscribe for the Anthem Biosciences IPO, which so far has gathered a lot of attention ...

According to market observers, shares of the company are available at a premium of ₹101 in the grey market today ...

Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, ...

The Rs 3,395 crore IPO of Anthem Biosciences closes for bidding today, July 16. With a rising GMP of Rs 156, the stock may list at Rs 726, offering a 27% gain.

Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...

Anthem ticks all the boxes. But with lofty valuations and limited margin headroom, analysts warn the IPO may not deliver ...